MAP1LC3B and myelodysplastic syndrome: The expression of LC3B in GlycoA+ NRBC in high-risk MDS patients (n = 23, 0.22 ± 0.12) was lower than that in controls (n = 22, 0.43 ± 0.22, P = 0.0003) and low-risk MDS patients (n = 21, 0.40 ± 0.16, P = 0.0001).